Literature DB >> 11380797

In vitro effect of thymosin-alpha1 and interferon-alpha on Th1 and Th2 cytokine synthesis in patients with chronic hepatitis C.

P Andreone1, C Cursaro, A Gramenzi, M Margotti, E Ferri, S Talarico, M Biselli, F Felline, C Tuthill, E Martins, G Gasbarrini, M Bernardi.   

Abstract

Current evidence suggests that increased expression of Th1-associated cytokines is important for immune-mediated eradication of hepatitis C infection, while an increase in Th2-associated cytokines is associated with persistence of infection. In this study we evaluated the effects of thymosin-alpha1 (TA1), a naturally occurring thymic peptide, and interferon-alpha (IFN-alpha) on cytokine production in peripheral blood mononuclear cells from untreated patients with chronic hepatitis C. We examined the effect of incubation with TA1, IFN-alpha, or both, on production of Th1-associated cytokines (IL-2, IFN-gamma), Th2-associated cytokines (IL-4, IL-10), and synthesis of the antiviral protein 2',5'-oligoadenylate synthetase. TA1 treatment induced a significant increase in production of IL-2 and 2',5'-oligoadenylate synthetase. Smaller increases were also seen after treatment with IFN-alpha, while incubation with TA1 and IFN-alpha together led to an additive or synergistic effect. Incubation with TA1 resulted in a decrease in IL-4 and IL-10, whereas IFN-alpha increased these cytokines. The addition of TA1 to IFN-alpha significantly reversed this IFN-alpha-induced increase. Hence, TA1 treatment could benefit patients with hepatitis C infection by increasing the Th1-type response, fundamental for sustained clearance of hepatitis C; and by decreasing the Th2-type response, associated with persistence of viraemia.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11380797     DOI: 10.1046/j.1365-2893.2001.00285.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  6 in total

1.  Immunomodulatory function of orally administered thymosin alpha1.

Authors:  Xiang-Ming Chen; Han-Liang Jiang; Lin-Fu Zhou; Xiao-Ping Pan; Zhong-Rong Hu; Rong-Hua Liu; Xiao-Ming Chen; Zhi Chen
Journal:  J Zhejiang Univ Sci B       Date:  2005-09       Impact factor: 3.066

2.  Thymosin Alpha-1 in Combination with Pegylated Interferon and Ribavirin in Chronic Hepatitis C Patients Who have Failed to Prior Pegylated Interferon and Ribavirin Treatment.

Authors:  Yang Hyun Baek; Sung Wook Lee; Hyun Seung Yoo; Hyun Ah Yoon; Ja Won Kim; Young Hoon Kim; Ha Youn Kim; Sang Young Han
Journal:  Gut Liver       Date:  2007-06-30       Impact factor: 4.519

3.  Advances in the Treatment of Hepatitis B and Hepatitis C Nonresponders: A Report of Symposia Presented at the 15th Conference of the Asian Pacific Association for the Study of the LiverAugust 18-21, 2005Bali, Indonesia.

Authors: 
Journal:  Gastroenterol Hepatol (N Y)       Date:  2006-01

4.  NMR structure of human thymosin alpha-1.

Authors:  Miguel-Angel Elizondo-Riojas; Steven M Chamow; Cynthia W Tuthill; David G Gorenstein; David E Volk
Journal:  Biochem Biophys Res Commun       Date:  2011-11-15       Impact factor: 3.575

5.  Potential Role of Thymosin-alpha1 Adjuvant Therapy for Glioblastoma.

Authors:  Arno Sungarian; Deus Cielo; Prakash Sampath; Nathaniel Bowling; Peter Moskal; Jack R Wands; Suzanne M de la Monte
Journal:  J Oncol       Date:  2010-01-11       Impact factor: 4.375

6.  Thymosin α1 Interacts with Hyaluronic Acid Electrostatically by Its Terminal Sequence LKEKK.

Authors:  Walter Mandaliti; Ridvan Nepravishta; Francesca Pica; Paola Sinibaldi Vallebona; Enrico Garaci; Maurizio Paci
Journal:  Molecules       Date:  2017-10-27       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.